D&D Pharmatech

2024 was an eventful year for the South Korean biopharma industry with the emergence of several key themes that look set to carry over into the new year. The sector is facing a new growth chapter fuel

More mid-stage clinical trial failures are piling up in the Parkinson’s disease space, with the latest disappointment coming from South Korea's Bukwang Pharmaceutical Co., Ltd. , underlining the diff

The news this week that a GLP-1 agonist had succeeded in improving the symptoms of Parkinson’s disease was curious for two reasons: one, several trials of similar incretins in the condition have faile

Venture capital (VC) investment sentiment appears to be changing in the South Korean healthcare sector. The shift became more apparent towards the end of the first quarter, amid keen interest in AI-ba